Birgitte Krogsgaard
@B_Krogsgaard
Followers
123
Following
49
Media
0
Statuses
23
MD, PhD fellow at Aarhus University Hospital, Dept. of Cardiology, Denmark. Investigating image-based coronary physiology @FAVORIIITrial
Aarhus, Denmark
Joined July 2013
RT @PCRonline: Coronary revascularisation deferral based on QFR or FFR: a post-hoc analysis 🔎 of the FAVOR III Europe trial. @drgocchipin….
0
6
0
Important insights from the @FAVORIIITrial . Despite a 21% increase in PCI rate when using QFR, the occurrence of MACE was higher following revascularisation deferral by QFR than by FFR. @JEscaned @NielsRHolm @h_evald.
❌NEW AHEAD OF PRINT❌."Coronary revascularisation deferral based on quantitative flow ratio or fractional flow reserve: a post hoc analysis of the FAVOR III Europe trial" @JEscaned .#Cardiology #CoronaryArteryDisease #PCI #ClinicalResearch.Read the full article:
0
0
4
A great summary of the findings in the @FAVORIIITrial by @TCTMD, with important comments by @mmamas1973 and @JoostDaemen .Several substudies in the pipeline - hopefully adding further insights soon. #TCT2024 #QFR #RCT #CardioTwitter.
0
0
8
RT @mmamas1973: Congratulations @NielsRHolm and @B_Krogsgaard for delivering the FAVOR III Europe Trial. Honored to provide the commentary….
0
9
0
RT @crfheart: FAVOR III Europe trial results are in! 🌍 QFR-based strategy in coronary physiology doesn’t match FFR for clinical outcomes at….
0
15
0
I am proud of our team work in both conducting and reporting the @FAVORIIITrial. Publication is now available online in @TheLancet . @NielsRHolm @h_evald.
Presented today at #TCT2024:. Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial @TCTConference
3
6
36
RT @EmilHolckMD: #QFR is NOT non-inferior to #FFR. Findings from the @FAVORIIITrial at #TCT2024 . @AUHCardio @NielsRHolm @B_Krogsgaard @h_e….
0
1
0
0
6
0
RT @CMichaelGibson: Angio derived Quantitative Flow Reserve inferior to wire based FFR in FAVOR 3. #TCT2024 View it here: .
0
5
0
RT @NielsRHolm: 1/x #QFR did not meet non-inferiority to FFR in the @FAVORIIITrial Europe presented by @B_Krogsgaard The 1-year primary EP….
0
16
0
RT @crfheart: Get ready to witness groundbreaking data @ #TCT2024! In collaboration with @JAMA_current this session features:.✨TRISCEND II….
0
5
0
RT @EmilHolckMD: It’s late breaking day! . Watch @B_Krogsgaard from @AUHCardio presenting the main results of FAVOR III Europe at #TCT2024….
0
2
0
RT @NielsRHolm: @TCTMD Interview with @B_Krogsgaard @wfearonmd and @mmamas1973 on the @FAVORIIITrial - LBT presentation #TCT2024 Wednesda….
0
6
0
RT @NielsRHolm: @FAVORIIITrial on QFR vs FFR to be presented as LBT 30. October at #TCT2024 - Methods paper here: h….
0
6
0
RT @NielsRHolm: Primary endpoint of the @FAVORIIITrial on QFR vs. FFR is presented on 30. October at #TCT2024 .#qfr #randomizedtrial #cardi….
0
11
0
RT @FAVORIIITrial: Yesterday, prof. @GianlucaCampo78 and his team in Ferrara enrolled patient no 1000 in the @FAVORIIITrial. Ferrara is als….
0
9
0
RT @FAVORIIITrial: This morning, we reached a major milestone in the FAVOR III trial! Patient number 500 was enrolled by dr. Hernán Mejía-R….
0
3
0
RT @monaltiren: POST-PCI FUNCTIONAL ASSESSMENT - new comprehensive review @WijnsWilliam @djc795 @WestraJelmer @NielsRHolm .
0
11
0